To provide long-term capital growth from a portfolio primarily invested in UK equities.
Name | % Net Assets |
---|---|
BG | 6.7% |
Vodafone | 6.5% |
GlaxoSmithKline | 5.2% |
AstraZeneca | 4.6% |
FirstGroup | 3.5% |
Venture Production | 3.4% |
Pearson | 3.1% |
Scottish & Southern Energy | 3.0% |
HSBC | 3.0% |
RSA Group | 2.8% |
Key | % Net Assets |
---|---|
BG | 6.7% |
Vodafone | 6.5% |
GlaxoSmithKline | 5.2% |
AstraZeneca | 4.6% |
Other | 77% |
Date | 21-Nov-2024 |
---|---|
NAV | 135.63p |
Currency | GBP |
Change | 0.26p |
% | 0.19% |
YTD change | 3.57p |
YTD % | 2.70% |
Fund Inception | 29/11/1999 |
---|---|
Fund Manager | Chris Watt |
TER | 1.71 (31-Oct-2013) |
Minimum Investment | |
---|---|
Initial | £500 |
Additional | n/a |
Savings | £100 |
Charges | |
---|---|
Initial | 5.25% |
Annual Mang't | 1.50% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.01 |
Sharpe ratio | 0.27 |
You are here: research